The European Medicines Agency (EMA) has just over 15 months to prepare for the move to Amsterdam by 30th March 2019. The Management Board of the EMA held a meeting to discuss how the Agency is preparing for the relocation to Amsterdam, and operationally for the United Kingdom’s (UK) withdrawal from the European Union (EU).
A delegation from the Dutch government was present for part of the Management Board meeting. The delegates stated next steps with regards to the relocation process and explained how the Dutch authorities plan to meet EMA’s requirements. EMA’s new permanent headquarters will be the tailor-made Vivaldi building which is due for completion in November 2019. Temporary premises will be offered to the EMA from 1st January 2019, or earlier if necessary, for an interim period until the new building is ready.
A permanent Netherlands helpdesk has been set up within the EMA, offering guidance to staff on practical aspects to help facilitate their relocation to the Netherlands. EMA and the Dutch authorities are also currently working on a Memorandum of Understanding (MoU).
In order to free up further resources needed to prepare for the withdrawal of the UK from the EU, the EMA’s Brexit preparedness business continuity plan will enter Phase 2 in January 2018. Transparent information on the details of the plan will be published as part of the 2018 work programme.
A methodology for the redistribution of the work currently carried out by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has been developed by the EU27 Member States and the EMA. The EMA will communicate details of the methodology and next steps in early 2018.
To read more about the Brexit update and adoption of work programme and budget for 2018, please click here.